CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $76,677 | +197.8% | 2,578,199 | +80.4% | 0.01% | +175.0% |
Q2 2023 | $25,750 | +3731.8% | 1,428,910 | +3319.8% | 0.00% | – |
Q1 2023 | $672 | -29.3% | 41,783 | -19.5% | 0.00% | – |
Q4 2022 | $951 | -99.9% | 51,931 | -15.7% | 0.00% | – |
Q3 2022 | $1,212,000 | +19.4% | 61,635 | +13.3% | 0.00% | – |
Q2 2022 | $1,015,000 | +23.0% | 54,407 | +44.8% | 0.00% | – |
Q1 2022 | $825,000 | -62.2% | 37,583 | -51.1% | 0.00% | – |
Q4 2021 | $2,183,000 | +56.7% | 76,822 | +16.1% | 0.00% | – |
Q3 2021 | $1,393,000 | +12.1% | 66,163 | +0.4% | 0.00% | – |
Q2 2021 | $1,243,000 | +66.4% | 65,925 | +34.9% | 0.00% | – |
Q1 2021 | $747,000 | -34.6% | 48,865 | -39.6% | 0.00% | – |
Q4 2020 | $1,142,000 | -15.3% | 80,902 | -6.0% | 0.00% | – |
Q3 2020 | $1,349,000 | -10.5% | 86,068 | 0.0% | 0.00% | – |
Q2 2020 | $1,508,000 | +260.8% | 86,068 | +203.0% | 0.00% | – |
Q1 2020 | $418,000 | -53.9% | 28,408 | -21.3% | 0.00% | – |
Q4 2019 | $906,000 | +15.3% | 36,108 | -30.9% | 0.00% | – |
Q3 2019 | $786,000 | -93.6% | 52,283 | -89.3% | 0.00% | -100.0% |
Q2 2019 | $12,198,000 | +10.2% | 487,916 | +0.4% | 0.00% | 0.0% |
Q1 2019 | $11,064,000 | -15.0% | 486,130 | +12.0% | 0.00% | 0.0% |
Q4 2018 | $13,016,000 | +4.7% | 433,996 | +0.0% | 0.00% | 0.0% |
Q3 2018 | $12,431,000 | – | 433,905 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |